YPYves Poulin

Yves Poulin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yves Poulin has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Anne-Julie Gaudreau

    Medical Affairs, Amgen Canada Inc., Mississauga, Ontario, Canada

    1 shared publication
  • Catherine Beauchemin

    5622 Hôpital Hôtel-Dieu de Québec and Pharmacoeconomics and Outcomes Research, PeriPharm Inc., Montréal, Canada

    1 shared publication
  • Catherine Royer

    5622 Hôpital Hôtel-Dieu de Québec and Pharmacoeconomics and Outcomes Research, PeriPharm Inc., Montréal, Canada

    1 shared publication
  • Chih-Ho Hong

    Probity Medical Research, Waterloo, ON, Canada

    1 shared publication
  • Christopher Tehlirian

    Pfizer Inc, Cambridge, MA, USA

    1 shared publication
  • Clarabella Yim

    Health Economics and Outcomes Research, Celgene Inc., Mississauga, Ontario, Canada

    1 shared publication

Latest Publications

  • TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

    by Seth B. Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth M. Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, et al.


  • Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization

    by Yves Poulin, Catherine Beauchemin, Catherine Royer, Anne-Julie Gaudreau, Clarabella Yim, Fei Fei Liu, Jean Lachaine

    In Québec, targeted biologic therapies for moderate to severe plaque psoriasis are restricted to patients who have not responded to phototherapy or conventional systemic treatment, primarily due to high drug costs. Apremilast, an oral treatment for plaque psoriasis, was added to the Québec provincial health insurance plan (Régie de l’assurance maladie du Québec; RAMQ) formulary in 2015, making this the only province in Canada with public drug plan reimbursement for apremilast. The aim of this study is to describe patients’ characteristics, treatment patterns, healthcare resource utilization (HCRU), and associated costs and to measure real-world budget impact of using apremilast before biologics in plaque psoriasis. This study was performed using RAMQ drug claims and medical services data. Patients diagnosed with psoriasis between January 2015 and December 2017 were identified. Medical services and prescription claims were categorized as all-cause and psoriasis-related. Using RAMQ database estimates, a 3-year budget impact analysis was developed comparing treatment cost with and without the addition of apremilast to the formulary. In all, 540 patients were identified (apremilast: n = 92; biologics: n = 448). Comorbidity burden and treatment persistence and adherence were comparable between apremilast and biologic users. The year following the index date, all-cause HCRU was lower for apremilast versus biologic users (CAN$19 763 vs CAN$28 025; P < .01), mainly driven by drug cost. Using apremilast before biologics resulted in an estimated RAMQ net savings of CAN$49 290 (2015), CAN$746 856 (2016), and CAN$1 216 512 (2017), and a total savings of CAN$2 012 658 since apremilast’s addition to the formulary. Adding apremilast to the drug formulary of other Canadian provinces could result in significant healthcare savings.


  • Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper

    by Jensen Yeung, Melinda J. Gooderham, Parbeer Grewal, Chih-Ho Hong, Perla Lansang, Kim A. Papp, Yves Poulin, Irina Turchin, Ronald Vender

    Background: Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of biologic therapies to treat PsO, guidance on disease management in WOCBP is needed to inform treatment decisions before, during, and after pregnancy. Objectives: To develop a practical, up-to-date consensus document, based on available evidence and expert opinion where evidence was lacking, in order to guide both Canadian and international clinicians treating PsO in WOCBP. Methods: A panel of 9 Canadian dermatologists with extensive clinical experience managing PsO reviewed the relevant literature from the past 25 years in 3 key domains: overview of PsO in WOCBP and clinical considerations, treatment considerations, and postpartum considerations. The structured literature search focused on WOCBP treated with TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), IL-12/23 inhibitors (ustekinumab), and IL-17 inhibitors (brodalumab, ixekizumab, secukinumab). This literature review, along with clinical expertise and opinion, was used to develop concise and clinically relevant consensus statements to guide practical management of PsO in WOCBP. Experts voted on the statements using a modified Delphi process and prespecified agreement cut-off of 75%. Results and implications: After review, discussion, and voting on 19 draft consensus statements at an in-person meeting and remotely, 12 consensus statements were approved by the expert panel. The statements presented here will guide healthcare providers in practical disease management using biologic therapies for the treatment of PsO in WOCBP.


  • Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population

    by Kim Papp, Fernando Valenzuela, Yves Poulin, Geula Bernstein, Norman Wasel

    Background: Limited data are available on the epidemiologic features of psoriasis in Canada. Objective: To investigate the epidemiologic features and burden of moderate-to-severe psoriasis in a Canadian population. Methods: An online survey was conducted using a consumer panel. Eligible respondents indicated a diagnosis of psoriasis and plaque-type psoriasis of at least moderate severity. Eligibility was validated according to self-reported body surface area (BSA) involvement, sensitive areas affected, and/or current treatment. Results: Of the 514 respondents who completed the survey, 62% estimated a BSA involvement of ≥ 3% within the past 5 years. Onset of psoriasis occurred earlier in females than in males. Nail involvement was more commonly reported in individuals with psoriatic arthritis compared to those without. Several symptoms were more likely described as “constantly” or “near constantly” experienced by females than by males. Comorbidities commonly reported were hypertension, dyslipidemia, and overweight or obesity. Conclusions: The findings are consistent with a substantial burden attributed to moderate-to-severe plaque psoriasis in a Canadian population.